AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14747423
Drug: Enalapril (low-tissue-penetrating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (low-tissue-penetrating ACE inhibitor)
Trial: 1842749
Drug: Miglitol, 50
RxNorm normalized name: Miglitol, 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miglitol, 50 mg three times a day
Trial: 342626
Drug: Whole-virus bivalent
RxNorm normalized name: INFLUENZA A VIRUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-virus bivalent influenza vaccine
Trial: 342626
Drug: Ether-split bivalent
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ether-split bivalent influenza vaccine
Trial: 27883203
Drug: Platform-switched implant-abutment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platform-switched implant-abutment connection
Trial: 27883203
Drug: Conventional platform-matched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional platform-matched implant-abutment connection
Trial: 15195074
Drug: Busulphan (BU)
RxNorm normalized name: Busulphan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulphan (BU) 150 mg/m2 given as four single daily doses
Trial: 15195074
Drug: Busulphan (BU)
RxNorm normalized name: Busulphan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulphan (BU) 4 mg/kg given as four single daily doses
Trial: 10367611
Drug: Active antihypertensive
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active antihypertensive medication
Trial: 10319538
Drug: Ketotifen 2
RxNorm normalized name: ketotifen 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen 2 mg
Trial: 1323811
Drug: Preoperative Cisplatin/Etoposide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative Cisplatin/Etoposide with concurrent thoracic irradiation
Trial: 6507909
Drug: Midazolam hydrochloride
RxNorm normalized name: Midazolam Hydrochloride
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam hydrochloride (5 mg/ml)
Trial: 6507909
Drug: Midazolam maleate
RxNorm normalized name: midazolam maleate
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam maleate (2.5 mg/ml)
Trial: 20581689
Drug: High CRP
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High CRP (>3 mg/L)
Trial: 21784046
Drug: Individualized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized treatment (24-72 weeks)
Trial: 21784046
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (48 weeks)
Trial: 21784046
Drug: Individualized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized treatment (24-30 weeks) for rapid responders
Trial: 21784046
Drug: Individualized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized treatment (60-72 weeks) for slow responders
Trial: 17177749
Drug: Intense pulsed
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense pulsed light (IPL) treatment with retinyl-based cream
Trial: 17177749
Drug: Intense pulsed
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense pulsed light (IPL) treatment only
Trial: 13679494
Drug: Tertatolol (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tertatolol (5-10 mg/day)
Trial: 8638692
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no rhGH treatment)
Trial: 1587426
Drug: Oral erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral erythromycin (500 mg)
Trial: 1420750
Drug: Intravenous erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous erythromycin (1.8 mg/kg)
Trial: 1420750
Drug: Oral erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral erythromycin (500 mg) b.d.
Trial: 20452749
Drug: Psychosocial treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychosocial treatment
Trial: 15121485
Drug: Aprepitant 10
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant 10 mg
Trial: 21397770
Drug: Besifloxacin ophthalmic
RxNorm normalized name: besifloxacin ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days
Trial: 21397770
Drug: Vehicle administered
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle administered twice daily for 3 days
Trial: 16781589
Drug: Traumeel S
RxNorm normalized name: Traumeel S Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traumeel S ointment
Trial: 16781589
Drug: Diclofenac 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 1% gel
Trial: 7742723
Drug: Oral folic
RxNorm normalized name: folic acid Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral folic acid (5 mg) daily for 6 months
Trial: 7742723
Drug: Placebo (similar-appearing)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (similar-appearing) daily for 6 months
Trial: 7742723
Drug: Oral folic
RxNorm normalized name: folic acid Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral folic acid (5 mg)
Trial: 2201724
Drug: Zopiclone (ZOP,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zopiclone (ZOP, 7.5 mg)
Trial: 2201724
Drug: Triazolam (TRZ,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (TRZ, 0.25 mg) + Alcohol (0.8 g/kg)
Trial: 2201724
Drug: Zopiclone (ZOP,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zopiclone (ZOP, 7.5 mg) + Alcohol (0.8 g/kg)
Trial: 7018605
Drug: Standard formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard formulation
Trial: 7018605
Drug: Alternative formulation
RxNorm normalized name: Yellow fever vaccine live - alternative formulation for vaccine shortage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative formulation
Trial: 19702927
Drug: Family‐focused therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family‐focused therapy (FFT)
Trial: 11509190
Drug: Smoked marijuana
RxNorm normalized name: Picea mariana resin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoked marijuana (8.4 and 16.9 mg THC)
Trial: 27609846
Drug: Postoperative intravenous
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative intravenous parecoxib sodium followed by oral celecoxib
Trial: 27609846
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with opioids as rescue treatment
Trial: 23725316
Drug: Biological management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological management of caries with best practice prevention
Trial: 20578610
Drug: Clonidine tablet
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine tablet at the dose of 5 microg/kg
Trial: 18400709
Drug: Dark chocolate
RxNorm normalized name: Ensure Original Dark Chocolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dark chocolate and cocoa (37-g dark chocolate bar and 8 ounces of artificially sweetened cocoa beverage daily for 6 weeks
Trial: 18400709
Drug: Placebo (similar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (similar placebo products daily for 6 weeks)
Trial: 16102908
Drug: Sustained-release methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release methylphenidate
Trial: 12527318
Drug: Painful infusion
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Painful infusion of hypertonic saline in the FDI muscle
Trial: 19299805
Drug: Lidocaine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (5 mg/kg)
Trial: 10588558
Drug: Amantadine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine (2.5 mg/kg)
Trial: 29781900
Drug: Nonablative fractional
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonablative fractional laser (NAFL) treatment on one half of the face
Trial: 29781900
Drug: Low-dose isotretinoin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose isotretinoin (10 mg/day)
Trial: 22757665
Drug: NAFL treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAFL treatment
Trial: 23946152
Drug: Ritonavir-boosted danoprevir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir-boosted danoprevir (DNVr) 100/100 mg twice/day
Trial: 23946152
Drug: Methadone maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone maintenance therapy (MMT) alone
Trial: 15917111
Drug: PCECV (Purified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCECV (Purified Chick Embryo Cell Vaccine) administered intradermally at 0.1 mL with antigen corresponding to 0.32 IU per intramuscular dose
Trial: 15917111
Drug: Current WHO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current WHO recommendations for vaccine potency (2.5 IU per intramuscular dose)
Trial: 8600871
Drug: Home program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home program of physical therapy (6-week program including ROM exercises, low resistance isometric and eccentric exercises of hip abductors)
Trial: 8600871
Drug: Home program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home program of physical therapy (all programs for group B)
Trial: 1817942
Drug: Rectal Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rectal Midazolam sedation
Trial: 1817942
Drug: Oral Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral Midazolam sedation
Trial: 7258126
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid supplementation (1.8 g daily for 10 children, 1.5 g daily for 10 children)
Trial: 31173468
Drug: Antiviral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral treatment for HBV (HBV DNA < 20 IU/mL after 48 weeks)
Trial: 31173468
Drug: Antiviral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral treatment for HCV (SVR-12)
Trial: 31173468
Drug: Post-treatment PRO
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment PRO scores
Trial: 23988398
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (blinded random allocation to trial treatment or placebo)
Trial: 22264599
Drug: Cognitive adaptation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive adaptation training combined with assertive community treatment (CAT+ACT)
Trial: 22264599
Drug: Assertive community
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assertive community treatment alone (ACT)
Trial: 17211096
Drug: ED-71 treatment
RxNorm normalized name: Ed-APAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ED-71 treatment for 12 months
Trial: 17211096
Drug: ED-71 treatment
RxNorm normalized name: Ed-APAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ED-71 treatment
Trial: 15526112
Drug: Electrogalvanic stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrogalvanic stimulation (EGS) twice a week
Trial: 15526112
Drug: Local injection
RxNorm normalized name: Sclerosing agents for local injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local injection of 40-mg triamcinolone acetonide mix with 1 ml 2% lidocaine
Trial: 11564134
Drug: Levocetirizine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocetirizine (10 mg)
Trial: 7843964
Drug: 3% NaCl
RxNorm normalized name: LVP solution Dextrose 5% with 0.3% NaCl intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% NaCl solution baths
Trial: 3152422
Drug: Sodium nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sodium nitroprusside with oral captopril pretreatment
Trial: 28985328
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (systolic blood pressure target <120 mm Hg)
Trial: 28985328
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (systolic blood pressure target <140 mm Hg)
Trial: 28985328
Drug: Overall model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall model (both treatment arms)
Trial: 25352300
Drug: lamivudine plus
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: lamivudine plus adefovir dipivoxil (ADV) combination therapy (COMBO)
Trial: 25352300
Drug: lamivudine monotherapy
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: lamivudine monotherapy (MONO)
Trial: 25352300
Drug: lamivudine monotherapy
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: lamivudine monotherapy (MONO) with early virological response
Trial: 23314393
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg amphetamine (AMPH)
Trial: 11928585
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose tolerance test (75 g)
Trial: 11928585
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose tolerance test and glycemia at 120 min exceeding 11.1 mmol/l
Trial: 1948658
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no steroids)
Trial: 2877576
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg intravenous famotidine
Trial: 2877576
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg intravenous famotidine
Trial: 2877576
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg oral famotidine
Trial: 16159618
Drug: ASHMI group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASHMI group (oral ASHMI capsules and prednisone placebo tablets)
Trial: 16159618
Drug: Prednisone group
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone group (oral prednisone tablets and ASHMI placebo capsules)
Trial: 12669132
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of n-3 polyunsaturated fatty acids (PUFAs)
Trial: 12669132
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of n-3 PUFAs
Trial: 12669132
Drug: Additional statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional statin treatment
Trial: 10550467
Drug: Alendronate 10
RxNorm normalized name: ALENDRONATE 10MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate 10 mg once daily for 1 year
Trial: 8727863
Drug: Sulfadiazine 500
RxNorm normalized name: sulfadiazine 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadiazine 500 mg/Trimethoprim 160 mg twice daily
Trial: 8348278
Drug: Active laser
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active laser treatment (CB Medico Master III 830 nm Ga As AL diode)
Trial: 8348278
Drug: Dummy laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dummy laser treatment
Trial: 3528278
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline plus hydrocortisone (100 mg daily)
Trial: 3528278
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (1 l/day)
Trial: 17512232
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human growth hormone (rhGH) 0.019 mg kg(‐1) day(‐1) for 6 days
Trial: 15459211
Drug: Doxorubicin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 60 mg/m² plus cisplatin 50 mg/m² every 3 weeks
Trial: 15459211
Drug: Doxorubicin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 60 mg/m²
Trial: 9210675
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg orally every 12 hours
Trial: 9210675
Drug: Ciprofloxacin 400
RxNorm normalized name: ciprofloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 400 mg intravenously
Trial: 3689614
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine 0.8 mg (group A)
Trial: 3689614
Drug: i.m. papaveretum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.m. papaveretum 10 mg (group B)
Trial: 29451991
Drug: βHB (d‐β‐hydroxybutyrate)
RxNorm normalized name: Citalopram Hydrobromide
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: βHB (d‐β‐hydroxybutyrate) beverage (11.38 g)
Trial: 11193281
Drug: Protein C
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein C and tissue factor-pathway inhibitor
Trial: 9033197
Drug: maximal regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: maximal regimen including daily clofazimine
Trial: 9033197
Drug: maximal regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: maximal regimens including daily rifampicin
Trial: 1670744
Drug: Doxazosin (4.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (4.7 mg daily)
Trial: 1670744
Drug: Prazosin (6.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (6.7 mg daily)
Trial: 6138086
Drug: Midazolam (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (15 mg p.o.)
Trial: 28355198
Drug: F130 (130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F130 (130 mg of OPN/L)
Trial: 28355198
Drug: F65 (65
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F65 (65 mg of OPN/L)
Trial: 25151265
Drug: Ablation or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ablation or silencing of GABAergic neurons or disruption of metabotropic GABA receptor 1 and 2 (GABA B R1/2) signaling in astrocytes
Trial: 22300419
Drug: Midazolam pharmacokinetics
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam pharmacokinetics model based on infants, toddlers, and adults (model 1)
Trial: 22300419
Drug: Midazolam pharmacokinetics
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam pharmacokinetics model based on children and adolescents (model 2)
Trial: 17721040
Drug: Existing drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Existing drugs (e.g., non‐steroidal anti‐inflammatory drugs, vitamins, and imatinib mesylate)
Trial: 16586188
Drug: 4 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 micrograms 1‐alpha‐hydroxyvitamin D(2) (1‐alpha D(2)) administered daily for 24 months
Trial: 16586188
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered daily for 24 months
Trial: 9858106
Drug: Insulin treatment
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin treatment (n = 18)
Trial: 9858106
Drug: Sulfonylurea treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfonylurea treatment (n = 16)
Trial: 7890127
Drug: Parenteral amino
RxNorm normalized name: parenteral amino acid 7 % comb no.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral amino acid preparation causing high plasma amino acid levels
Trial: 7890127
Drug: Parenteral amino
RxNorm normalized name: parenteral amino acid 7 % comb no.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral amino acid preparation with normal plasma aminogram levels
Trial: 26280156
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate (MMF) 0.1% ointment, applied once daily for 5 days per week for 4 weeks, then on alternate days for 4 weeks, then twice weekly for 4 weeks (group A)